ProMIS Neurosciences (PMN) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Telomir Pharmaceuticals (TELO) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 30.3% versus a loss of 35.8%. Telomir Pharmaceuticals is the larger company by market cap ($84.7 million vs $82.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMN | TELO |
|---|---|---|
| Share price | $9.15 | $1.15 |
| Market cap | $82.05M | $84.66M |
| 1-day change | +0.33% | +2.68% |
| YTD return | +33.97% | -13.53% |
| 1-year return | -35.79% | -30.30% |
| 5-year return | -95.93% | — |
| EPS (TTM) | $-11.65 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.40 | $1.82 |
| 52-week low | $6.27 | $0.888 |
| Distance from 52-week high | -66.61% | -36.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +365.68% | +247.83% |
| Average volume | 84.01K | 97.98K |
| Shares outstanding | 8.97M | 73.62M |
| Employees | 10 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Healthcare · Biotechnology · 10 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Healthcare · Biotechnology
PMN vs TELO FAQ
Which is bigger, ProMIS Neurosciences or Telomir Pharmaceuticals?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $84.66M compared with $82.05M for ProMIS Neurosciences (PMN).
Which stock has performed better over the past year, PMN or TELO?
TELO returned -30.30% over the past 12 months, compared with -35.79% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are ProMIS Neurosciences and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.